4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating restated by investment analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

A number of other research firms have also issued reports on FDMT. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $40.00 to $15.00 in a report on Monday, January 13th. Morgan Stanley reduced their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. Cantor Fitzgerald cut 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Bank of America dropped their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $38.56.

4D Molecular Therapeutics Stock Down 2.1 %

Shares of FDMT stock traded down $0.10 during trading hours on Friday, reaching $4.58. 927,608 shares of the stock traded hands, compared to its average volume of 992,118. The firm has a market capitalization of $211.73 million, a PE ratio of -1.61 and a beta of 2.81. 4D Molecular Therapeutics has a 1-year low of $4.50 and a 1-year high of $36.25. The business has a fifty day moving average price of $6.66 and a 200 day moving average price of $11.49.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of FDMT. Assenagon Asset Management S.A. raised its holdings in 4D Molecular Therapeutics by 238.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after acquiring an additional 1,087,147 shares during the period. Braidwell LP raised its stake in shares of 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after acquiring an additional 855,990 shares during the last quarter. Redmile Group LLC boosted its stake in 4D Molecular Therapeutics by 17.6% in the third quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock worth $13,643,000 after purchasing an additional 188,655 shares in the last quarter. Novo Holdings A S grew its holdings in 4D Molecular Therapeutics by 7.1% during the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $16,215,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Squarepoint Ops LLC increased its position in 4D Molecular Therapeutics by 652.7% in the 2nd quarter. Squarepoint Ops LLC now owns 110,041 shares of the company’s stock valued at $2,310,000 after acquiring an additional 95,422 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.